rgan_anley_Biopharma_April_oncology_sales_performance_

Key Points Industry: Biopharma | North America * Overall Market: The biopharma industry in North America is experiencing growth, with various therapies showing positive sales trends. * Oncology: Oncology drugs, particularly immuno-oncology therapies, are driving growth in the biopharma industry. Key players include Bristol Myers Squibb (Opdivo, Yervoy), Merck (Keytruda), and AstraZeneca (Lynparza). * BTK Inhibitors: BTK inhibitors are also a significant growth area, with drugs like Imbruvica, Calquence, and Brukinsa showing strong sales growth. * Biosimilars: Biosimilars are gaining market share, with examples including Neulasta, Avastin, and Herceptin biosimilars. Companies * Bristol Myers Squibb (BMY): * Opdivo and Yervoy are leading oncology drugs, with strong sales growth. * Opdivo sales by indication: NSCLC (25%), Melanoma (15%), RCC (10%), HNSCC (5%), Urothelial Carcinoma (5%), and others (5%). * Keytruda sales by indication: NSCLC (24%), Melanoma (8%), H&N (8%), Bladder (8%), MSI-High (11.2%), RCC (8%), TNBC (8%), and others (12.5%). * Merck (MRK): * Keytruda is a leading oncology drug, with strong sales growth. * Keytruda sales by indication: NSCLC (24%), Melanoma (8%), H&N (8%), Bladder (8%), MSI-High (11.2%), RCC (8%), TNBC (8%), and others (12.5%). * AstraZeneca (AZN): * Lynparza is a leading PARP inhibitor, with strong sales growth. * Lynparza received additional approvals for first-line maintenance therapy in ovarian cancer and metastatic castration-resistant prostate cancer. * AbbVie (ABBV): * Imbruvica is a leading BTK inhibitor, with strong sales growth. * Imbruvica sales by indication: MCL (50%), CLL (30%), Waldenstrom's Macroglobulinemia (10%), Marginal Zone Lymphoma (5%), and Chronic GVHD (5%). * Pfizer (PFE): * Bavencio and Imfinzi are leading immuno-oncology drugs, with strong sales growth. * Bavencio sales by indication: Melanoma (50%), NSCLC (25%), SCLC (25%), and others (0%). * Imfinzi sales by indication: NSCLC (50%), SCLC (25%), H&N (25%), and others (0%). * Johnson & Johnson (JNJ): * Erleada and Zytiga are leading androgen receptor inhibitors, with strong sales growth. * Erleada sales by indication: Castration-resistant prostate cancer (metastatic high-risk). * Zytiga sales by indication: Castration-resistant prostate cancer (non-metastatic). * Amgen (AMGN): * Kyprolis is a leading proteasome inhibitor, with strong sales growth. * Kyprolis sales by indication: Multiple Myeloma (100%). Other Important Points * IQVIA Sales Data: The report uses IQVIA sales data to analyze market trends and drug sales. * Normalization: Sales data is normalized to a 4-week basis to compare with other months. * Reporting Restrictions: Some drugs have reporting restrictions due to contractual conditions between suppliers and manufacturers. * Market Share: The report also analyzes market share for various drugs and therapies.